

b

**Appendix B**  
**Proposed Counts**  
**Proposed Count 1**

A composition comprising:

a plasmid including an immunostimulatory nucleic acid sequence comprising AACGTT, wherein C is unmethylated, and an antigen in a pharmaceutically acceptable carrier, wherein the antigen is encoded in the plasmid

OR

A composition comprising:

a plasmid including an immunostimulatory nucleic acid sequence, comprising:

5'X<sub>1</sub>X<sub>2</sub>CGX<sub>3</sub>X<sub>4</sub>3' wherein C is unmethylated, wherein X<sub>1</sub>, X<sub>2</sub>, X<sub>3</sub>, and X<sub>4</sub> are nucleotides and an antigen in a pharmaceutically acceptable carrier, wherein X<sub>1</sub>X<sub>2</sub> are nucleotides selected from the group consisting of: GpT, GpG, GpA and ApA; and X<sub>3</sub>X<sub>4</sub> are nucleotides selected from the group consisting of: TpT, CpT, GpT, and TpG.

**Proposed Count 2**

A method for suppressing an allergic response to an antigen in a mammal susceptible to an allergic reaction to said antigen which stimulates production of allergy-associated IgE antibodies in the mammal, comprising parenterally administering to the mammal

(a) an effective amount of an immunostimulatory nucleic acid in a plasmid, said immunostimulatory nucleic acid comprising 5'CG3', wherein C is unmethylated, and

(b) an effective amount of the antigen or the antigen encoded in the plasmid

OR

A method for desensitizing a subject against the occurrence of an allergic reaction in response to contact with a particular allergen, comprising administering to the subject an effective amount of an immunostimulatory nucleic acid, comprising:

5'X<sub>1</sub>CGX<sub>2</sub>3'

wherein the immunostimulatory nucleic acid includes at least 8 nucleotides and wherein C is unmethylated and wherein X<sub>1</sub> and X<sub>2</sub> are nucleotides and an effective amount of the allergen.